Folic Acid and Methotrexate: Two Very Different Interactions
Methotrexate is used for two very different purposes: as a disease-modifying drug in rheumatoid arthritis, psoriasis, and inflammatory bowel disease at low doses taken weekly; and as a chemotherapy agent in certain cancers at much higher doses. Both uses involve the same drug and the same biochemical mechanism, but the interaction with folic acid supplementation is nearly opposite between them. Understanding why requires understanding what methotrexate actually does at the cellular level.
What methotrexate does: blocking the folate pathway
Methotrexate inhibits dihydrofolate reductase (DHFR), the enzyme that converts dietary folate into its active, usable form. DHFR takes dihydrofolate (the partially reduced form) and converts it to tetrahydrofolate (THF), which the body needs for DNA synthesis — specifically for making the building blocks of new DNA strands. Cells that divide rapidly, whether rapidly dividing immune cells in an inflamed joint or cancer cells in a tumor, depend heavily on this pathway.
By blocking DHFR, methotrexate creates a relative folate deficiency in rapidly dividing cells. In cancer treatment, this is the therapeutic goal — the drug kills tumor cells by starving them of the folate-derived nucleotides they need to replicate their DNA. In rheumatoid arthritis, the anti-inflammatory mechanism operates partly through this pathway (impairing proliferating immune cells) but also through several other effects on adenosine signaling and immune regulation that are not folate-dependent.
In rheumatoid arthritis: folic acid is standard of care
At the low weekly doses used for RA (typically 7.5–25 mg per week), methotrexate depletes folate in all rapidly dividing cells, not just immune cells. The most common side effects of low-dose methotrexate — nausea, oral ulcers, GI discomfort, and elevated liver enzymes — appear to be largely driven by this broad folate depletion rather than by the specific anti-inflammatory mechanism. Co-prescribing folic acid reduces these side effects substantially, and randomized controlled trials have consistently shown that folic acid supplementation does not significantly reduce methotrexate's anti-inflammatory efficacy in RA patients.
The NIH ODS Folate fact sheet notes this interaction directly, identifying it as well-established: folic acid is routinely co-prescribed with low-dose methotrexate. This is not a contraindication — it is standard clinical practice. Someone with RA on methotrexate who takes a daily folic acid supplement (often 1 mg/day, sometimes 5 mg/week) is following their prescriber's guidance, not introducing a risk.
In cancer treatment: supplemental folate may reduce efficacy
At the high doses used in cancer chemotherapy, the anti-tumor mechanism depends directly on DHFR inhibition and the resulting folate starvation of cancer cells. Adding a folate supplement provides a reservoir of dietary folate that cancer cells may be able to use to partially overcome the blockade — in effect, partially rescuing the cells that methotrexate is trying to kill. This is why clinicians managing patients on methotrexate-based chemotherapy regimens typically advise against unsupervised supplementation with folate-containing vitamins, including high-dose multivitamins with significant B9 content.
The picture is more nuanced for some treatment protocols. Leucovorin (folinic acid), a form of active folate, is sometimes administered deliberately after high-dose methotrexate in cancer treatment as a "leucovorin rescue" — protecting normal cells once the tumor-targeting window has passed. This is a timed, supervised clinical protocol, not self-supplementation.
The practical implication: ask why you are taking methotrexate
The same supplement — folic acid — is actively encouraged for one group of methotrexate users and potentially harmful for another. The determining factor is the indication. For RA, psoriasis, or psoriatic arthritis at low weekly doses: folic acid supplementation is usually recommended by the prescribing physician, reduces side effects, and does not compromise the drug's benefit. For cancer chemotherapy: supplemental folate should be discussed explicitly with the oncology team before adding.
This makes methotrexate an unusual case where the supplement's safety cannot be determined without knowing why the drug is prescribed. Someone who has recently started methotrexate should ask their prescriber directly about folic acid — not assume the answer is yes or no based on general supplement guidance.